Related substances analysis and testing for Traditional Chinese Medicine (TCM) is a critical quality control process that identifies, quantifies, and controls impurities chemically associated with the active or marker constituents of herbal materials, extracts, and finished preparations. Using advanced chromatographic and spectrometric techniques such as HPLC-DAD, UHPLC-QTOF, LC-MS/MS, and GC-MS, this testing safeguards product safety, supports stability evaluation, and ensures regulatory compliance with the Chinese Pharmacopoeia and international guidelines. Professional testing laboratories provide comprehensive impurity profiling, stability-indicating method development, validation, and regulatory submission support for pharmaceutical manufacturers and research institutions.
Technical Overview
Related substances in Traditional Chinese Medicine refer to impurities that are chemically related to the active ingredients, marker compounds, or inherent toxic constituents of herbal products. These impurities typically include degradation products formed during processing, extraction, and storage; process-related impurities introduced during manufacturing; structural analogues and isomers co-extracted from the complex herbal matrix; and naturally occurring toxic components such as aristolochic acids, pyrrolizidine alkaloids, and diterpenoid alkaloids from aconite.
Unlike synthetic chemical drugs with well-defined molecular structures, TCM products are multi-component systems in which hundreds of primary and secondary metabolites coexist at widely varying concentrations. This complexity makes impurity profiling significantly more challenging: the analytical method must separate the target impurities from a dense background of structurally similar phytochemicals, and impurity limits must be established on a case-by-case basis considering pharmacological and toxicological data.
Related substances testing for TCM is governed by the Chinese Pharmacopoeia (2020 edition), the technical requirements of the National Medical Products Administration (NMPA) for TCM quality control, and internationally recognized principles adapted from ICH guidelines, including Q3A and Q3B for impurities, Q2(R2) for method validation, Q1A(R2) and Q1B for stability, and M7 for mutagenic impurities. For high-risk dosage forms such as TCM injections, impurity control requirements are considerably stricter, often requiring full impurity characterization and mass balance studies.
Testing Samples
Raw Herbal Materials and Decoction Pieces
Crude botanical, zoological, and mineral-derived materials are tested for inherent toxic constituents, contaminants introduced during cultivation and post-harvest handling, and markers of improper processing such as sulfur dioxide residues from excessive sulfur fumigation. Representative sampling and sample homogenization are critical at this stage because impurity distribution in herbal materials is often heterogeneous.
Herbal Extracts and Manufacturing Intermediates
Intermediate products, including total extracts, fractionated extracts, and purified active fractions, are analyzed for process-related impurities such as residual extraction solvents, degradation products generated during concentration and drying, and carry-over impurities from purification columns. Testing intermediates enables early identification of impurity sources and supports quality-by-design approaches.
Finished TCM Preparations
Tablets, capsules, granules, pills, oral liquids, tinctures, and topical formulations are tested for degradation products that develop during formulation, packaging, and shelf life. The presence of excipients and the diverse physicochemical properties of TCM formulations require sample preparation procedures such as solid-phase extraction and matrix-matched calibration to achieve accurate quantification.
TCM Injections and High-Risk Formulations
Injectable TCM preparations are subject to the most rigorous impurity control due to direct systemic administration. Testing covers degradation products, polymerizable impurities, residual auxiliary solvents, and any impurity exceeding identification or qualification thresholds, with full structural elucidation by high-resolution mass spectrometry where required.
Testing Items
A comprehensive related substances testing program for TCM typically encompasses the following categories, each with defined analytical strategies and acceptance criteria:
- Degradation products of active and marker constituents, including hydrolysis, oxidation, isomerization, and polymerization products
- Inherent toxic components such as aristolochic acid I, pyrrolizidine alkaloids, aconitine and its hydrolysis products, strychnine, and scopolamine-type alkaloids
- Process-related impurities, including residual monomers, reagents, and purification by-products
- Residual solvents from extraction, concentration, and granulation processes
- Sulfur dioxide residues resulting from sulfur fumigation of herbal materials
- Mycotoxin-related impurities such as aflatoxins B1, B2, G1, and G2 in susceptible herbal matrices
- Reporting parameters including individual known and unknown impurity levels, total impurity content, impurity profiles, and comparison against specification limits
Testing Methods
High-Performance Liquid Chromatography (HPLC-DAD/UV)
HPLC with diode-array detection is the workhorse technique for related substances analysis of TCM. Diode-array detection enables peak purity assessment and multi-wavelength monitoring, allowing simultaneous quantification of impurities with different UV absorption characteristics. Methods often employ gradient elution with reversed-phase columns and, where standards are available, quantification against reference substances or relative response factors.
Liquid Chromatography-Mass Spectrometry (LC-MS/MS and UHPLC-QTOF)
Triple quadrupole LC-MS/MS provides highly sensitive and selective quantification of trace toxic impurities at sub-ppm levels, which is essential for controlling inherently toxic constituents such as pyrrolizidine alkaloids and aristolochic acids. High-resolution QTOF mass spectrometry is used for structural elucidation of unknown impurities exceeding identification thresholds, supporting impurity qualification and mass balance studies.
Gas Chromatography (GC-FID and GC-MS)
Headspace GC-FID and GC-MS are applied to residual solvent determination and volatile impurity profiling, following the limit principles of ICH Q3C. Direct GC-MS analysis supports the characterization of volatile degradation products in essential-oil-containing preparations.
Complementary Detection Techniques
Evaporative light-scattering detection (ELSD), charged aerosol detection (CAD), and fluorescence detection extend impurity monitoring to compounds lacking UV chromophores, such as saponins, sugars, and certain terpenoids. HPTLC and TLC densitometry provide cost-effective screening and identity confirmation of impurity profiles in accordance with pharmacopoeial monographs.
Method Development, Forced Degradation, and Validation
Stability-indicating methods are developed and confirmed through forced degradation studies under acidic and basic hydrolysis, oxidative, thermal, and photolytic conditions in accordance with ICH Q1B. Validated methods must demonstrate specificity, linearity, accuracy, precision, quantitation limit, detection limit, range, and robustness as required by ICH Q2(R2) and the relevant general chapters of the Chinese Pharmacopoeia. Method transfer and verification protocols are also available for in-house quality control laboratories.
Applications
Related substances analysis and testing services for TCM support the full product lifecycle, from early development through commercial manufacturing and post-market surveillance:
- Quality control and batch release testing of herbal materials, extracts, and finished TCM preparations
- Stability studies under long-term, accelerated, and stress conditions, with impurity profiling at predefined time points for shelf-life determination
- Regulatory dossier support for NMPA drug registration, generic TCM filings, and supplementary applications requiring impurity data
- Safety evaluation of TCM injections and consistency evaluation of marketed products
- Investigation of impurity formation, source tracing, and manufacturing process optimization
- Compliance support for herbal health products, dietary supplements, and TCM products intended for export markets under FDA botanical guidance and EMA herbal quality requirements
- Vendor qualification and incoming material control programs for pharmaceutical manufacturers
FAQ
What are related substances in Traditional Chinese Medicine?
Related substances are impurities chemically related to the active or marker constituents of a TCM product. They include degradation products, co-extracted structural analogues, process-related impurities, and inherent toxic components. Because TCM matrices are complex natural systems, related substances testing focuses on both known toxic impurities and the overall impurity profile of the product.
How are impurity limits established for TCM products?
Impurity limits are established based on pharmacopoeial monographs, toxicological data, manufacturing experience, and stability results. For known toxic constituents, limits may be set at the parts-per-million level, while degradation product limits typically follow threshold principles adapted from ICH Q3A and Q3B, with individual unknown impurities commonly controlled at or below 0.10 percent for oral formulations and stricter limits for injectable products.
What standards govern related substances testing for TCM?
Primary standards include the Chinese Pharmacopoeia 2020 edition, NMPA technical guidelines for TCM quality research, and ICH guidelines on impurities, residual solvents, method validation, and stability. For products intended for international markets, FDA botanical drug guidance and EMA quality guidelines for herbal medicinal products also apply.
How are unknown impurities handled when they exceed thresholds?
When an unknown impurity exceeds an identification threshold, it is isolated or enriched and characterized using high-resolution LC-MS/MS, UV spectral analysis, and, where necessary, NMR spectroscopy. The identified structure is then assessed for potential toxicity, including in silico mutagenicity evaluation under ICH M7 principles, and a qualification strategy is proposed to the regulatory authority.
What sample information should be provided for testing?
Clients should provide the sample name, dosage form, intended testing scope, available reference standards, any known impurity information, and the applicable regulatory standard. Sufficient sample quantity is required depending on the dosage form, and samples should be shipped under conditions consistent with their storage requirements to prevent artificial impurity generation during transport.
What is the typical turnaround time for related substances testing?
Routine impurity quantification using established pharmacopoeial methods is generally completed within seven to fifteen working days. Projects involving method development, forced degradation studies, unknown impurity identification, and full validation typically require three to eight weeks depending on complexity, matrix interference, and the number of analytes involved.